Mechanisms of action of intravenous immune globulin in immune-mediated diseases

Clinical and Experimental Immunology, Supplement

Volumn 104, Issue SUPPL. 1, 1996, Pages 3-9

  Mouthon, L ^a   Kaveri, S V ^a   Spalter, S H ^a   Lacroix Desmazes, S ^a   Lefranc, C ^a   Desai, R ^a   Kazatchkine, M D ^a,b  

^a INSERM   (France)

^b HÔPITAL BROUSSAIS   (France)

Author keywords

Autoimmunity; Immunoglobulins; Inflammation; Intravenous immune globulin

Indexed keywords

AUTOANTIBODY; COMPLEMENT; CYTOKINE; FC RECEPTOR; IMMUNOGLOBULIN;

AUTOIMMUNITY; B LYMPHOCYTE; COMPLEMENT ACTIVATION; CONFERENCE PAPER; DRUG THERAPY; HUMAN; IMMUNOMODULATION; MACROPHAGE; PRIORITY JOURNAL; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; AUTOIMMUNE DISEASES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS;

EID: 0029920574     PISSN: 09642536     EISSN: None     Source Type: Journal    
DOI: 10.1111/cei.1996.104.s1.3     Document Type: Article

References (63)

1. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992; 326:107-16.
2. Blasczyk R, Westhoff U, Grossewilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 1993; 341:789-90.
3. Saoudi A, Hurez V, de Kozak Y et al. Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis. Int Immunol 1993; 5:1559-67.
4. Rossi F, Bellon B, Vial MC et al. Beneficial effect of human therapeutic intravenous immunoglobulins (IVIG) in mercuric-chloride-induced autoimmune disease of Brown-Norway rats. Clin Exp Immunol 1991; 84:129-33.
5. Achiron A, Margalit R, Hershkoviz R et al. Intravenous immunoglobulin treatment of experimental T-cell mediated autoimmune disease. Upregulation of T-cell proliferation and downregulation of tumour neurosis factor-α secretion. J Clin Invest 1994, 93:600-605.
6. Bakimer R, Guilburd B, Zurgil N, Shoenfeld Y. The effect of intravenous γ-globulin on the induction of experimental antiphospholipid syndrome. Clin Immunol Immunopathol 1993; 69:97-102.
7. Hentati B, Sato MN, Payelle-Brogard B et al. Beneficial effect of polyclonal immunoglobulins from malaria-infected Balb/c mice on lupus-like syndrome of (NZB x NZW)F1 mice. Eur J Immunol 1994; 24:8-15.
8. Andersson A, Forsgren S, Söderström A, Holmberg D. Monoclonal natural antibodies prevent development of diabetes in the nonobese diabetic (NOD) mouse. J Autoimmunity 1991; 4:733-42.
9. Hammarström L, Abedi MR, Hassan MS, Edward-Smith CI. The SCID mouse as a model for autoimmunity. J Autoimmunity 1993; 6:667-74.
10. Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gammaglobulin. N Engl J Med 1982; 306:1254-8.
11. Kimberly RP, Salmon JE, Bussel JB et al. Modulation of mononuclear phagocyte function by intravenous gamma globulin. J Immunol 1984; 132:745-50.
12. Clarkson SB, Bussel JB, Kimberly RP et al. Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N Engl J Med 1986; 314:1236-9.
13. Debré M, Bonnet MC, Fridman WH et al. Infusion of Fcγ fragments for the treatment of children with acute immune thrombocytopenic purpura. Lancet 1993; 342:945-9.
14. Salama A, Mueller-Eckhardt C, Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia. Competitive inhibition of reticuloendothelial system function by sequestration of autologous red blood cells? Lancet 1983; ii:193-5.
15. Basta M, Fries LF, Frank MM. High-dose intravenous immunoglobulin inhibits in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood 1991; 77:376-80.
16. Basta M, Langlois PF, Marques M et al. High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance. Blood 1989; 74:326-33.
17. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Inv 1994; 94:1729-35.
18. Andersson UG, Bjork L, Skansén-Saphir U, Andersson JP. Down-regulation of cytokine production and IL-2 receptor expression by pooled human IgG. Immunology 1993; 79:211-6.
19. Amran A, Renz H, Lack G et al. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 1994; 73:180-6.
20. Ling ZD, Yeoh E, Webb BT et al. Intravenous immunoglobulin induces interferon-γ and interleukin-6 in vivo. J Clin Immunol 1993; 13:302-9.
21. Andersson JP, Andersson UG. Human intravenous immunoglobulin modulates monokine production in vitro. Immunology 1990; 71:372-6.
22. Ruiz-de-Souza V, Carreno MP, Kaveri SV et al. Selective induction of IL-Ira and IL-8 in human monocytes bv normal polyspecific immunoglobulin G for therapeutic use (IVIG). Eur J Immunol 1995; 25:1267-73.
23. Arend WP, Smith MF, Janson RW, Joslin FG. IL-1 receptor antagonist and IL-1β production in human monocytes are regulated differently. J Immunol 1991; 147:1530-6.
24. Poutsiaka DD, Clark BD, Vannier E, Dinarello CA. Production of IL-receptor antagonist and IL-1β by peripheral blood mononuclear cells is differentially regulated. Blood 1991; 78:1275-9.
25. Leung D, Kurt-Jones E, Newburger J et al. Endothelial cell activation of high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet 1989; ii:1298-302.
26. Shimozato T, Iwata M, Kawada H, Tamura N. Suppression of tumor necrosis factor alpha production by a human immunoglobulin preparation for intravenous use. Infect Immun 1990; 58:1384-8.
27. Shimozato T, Iwata M, Kawada H, Tamura N. Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3′: 5′-monophosphate levels, resulting in suppression of tumor necrosis factor alpha and interleukin-1 production. Immunology 1991; 72:497-501.
28. Aukrust P, Froland SS, Liabakk NB et al. Release of cytokines, soluble cytokine receptors, and interleukin-I receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994; 84:2136-43.
29. Van Schaik IN, Lundkvist I, Vermeulen M, Brand A. Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro. J Clin Immunol 1992; 12:325-34.
30. Leung DYM, Gately M, Trumble A et al. Bacterial superantigens induce T cell expression of the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen, via stimulation of interleukin-12 production. J Exp Med 1995; 181:747-53.
31. Kawada K, Terasaki PI. Evidence for immunosuppression by high-dose gammaglobulin. Exp Hematol 1987; 15:133-6.
32. 2+-dependent signal transduction through Fcγ receptors in B lymphocytes. Scand J Immunol 1994; 40:37-42.
33. Hashimoto F, Sakiyama Y, Matsumoto S. The suppressive effect of gammaglobulin preparations on in vitro pokeweed mitogen-induced immunoglobulin production. Clin Exp Immunol 1986; 65:409-15.
34. Stohl W. Cellular mechanisms in the in vitro inhibition of pokeweed mitogen-induced B cell differentiation by immunoglobulin for intravenous use. J Immunol 1986; 136:4407-13.
35. Kondo N, Ozawa T, Mushiake K et al. Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin. J Clin Immunol 1991; 11:152-8.
36. Vassilev T, Gelin C, Kaveri SV et al. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulin, IVIG). Clin Exp Immunol 1993; 92:369-72.
37. Hurez V, Kaveri SV, Mouhoub A et al. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use (intravenous immunoglobulin, IVIG). Therap Immunol 1994; 1: 269-78.
38. Casali P, Notkins AL. Probing the human B-cell repertoire with EBV: Polyreactive antibodies and CD5+ B lymphocytes. Ann Rev Immunol 1989; 7:513-35.
39. Sullivan KM, Kopecky KG, Jocom J et al. Immunomodulatory and anti-microbial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Eng J Med 1990; 323:705-9.
40. Kaveri S, Vassilev T, Hurez V et al. Antibodies to a highly conserved α helix of HLA class I molecules in pooled normal immunoglobulin for therapeutic use (IVIG). J Clin Invest 1996; 96:865-69.
41. Atlas E, Freedman J, Blanchette V et al. Downregulation of the anti-HLA alloimmune response by variable region-reactive (anti-idiotypic) antibodies in leukemic patients transfused with platelet concentrates. Blood 1993; 81:538-42.
42. Glotz D, Haymann J-P, Sansonetti N et al. Suppression of allo-anti-HLA antibodies by high dose intravenous immunoglobulins (IVIG): a potential tool for transplantation of immunized patients. Transplantation 1993; 56:335-7.
43. Marchalonis JJ, Kaymaz H, Dedeoglu F et al. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor β chain. Proc Natl Acad Sci USA 1992; 89:3325-9.
44. Baudet V, Hurez V, Lapeyre C et al. Intravenous immunoglobulin modulates the expansion of Vβ3+ and Vβ17+ αβ T cells induced by superantigen in vitro. Scand J Immunol 1996; 43:277-82.
45. Takei S, Arora Y, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest 1993; 91:602-7.
46. Rossi F, Dietrich G, Kazatchkine MD. Anti-idiotypes against autoantibodies in normal immunoglobulins: evidence for network regulation of human autoimmune responses. Immunol Rev 1989; 110:135-49.
47. Ronda N, Haury M, Nobrega A et al. Selectivity of recognition of variable (V) regions of autoantibodies by intravenous immunoglobulin (IVIg). Clin Immunol Immunopathol 1994; 70:124-8.
48. Rossi F, Sultan Y, Kazatchkine MD. Anti-idiotypes against autoantibodies and alloantibodies to Factor VIII:C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. Clin Exp Immunol 1988; 74:311-6.
49. Dietrich G, Kazatchkine MD. Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contains antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. J Clin Invest 1990; 85: 620-5.
50. Adib M, Ragimbeau J, Avrameas S, Ternynck T. IgG autoantibody activity in normal mouse serum is controlled by IgM. J Immunol 1990; 145:3807-13.
51. Hurez V, Kaveri SV, Kazatchkine MD. Expression and control of the natural autoreactive IgG repertoire in normal human serum. Eur J Immunol 1993; 23:783-9.
52. Ronda N, Haury M, Nobrega A et al. Analysis of natural and disease-associated autoantibody repertoires: anti-endothelial cell autoantibody activity in the serum of healthy individuals and patients with systemic lupus erythematosus. Int Immunol 1994; 5:1559-67.
53. Rossi F, Jayne DRW, Lockwood CM, Kazatchkine MD. Antiidiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin Exp Immunol 1991; 83:298-303.
54. Sultan Y, Rossi F, Kazatchkine MD. Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies. Proc Natl Acad Sci USA 1987; 84:828-31.
55. Mouthon L, Piketty C, Kazatchkine MD. Immunomodulation of autoimmune and systemic inflammatory diseases with intravenous immunoglobulin. Vox Sang 1994; 67(Suppl.3): 53-9.
56. Dietrich G, Algiman M, Sultan Y et al. Origin of anti-idiotypic activity against anti-factor VIII autoantibodies in pools of normal human immunoglobulin G (IVIg). Blood 1992; 79:2946-51.
57. Dietrich G, Kaveri SV, Kazatchkine MD. A V region-connected autoreactive subfraction of normal human serum immunoglobulin G. Eur J Immunol 1992; 22:1701-6.
58. Roux KH, Tankersley DL. A view of the human idiotypic repertoire: electron microscopic and immunologic analyses of spontaneous idiotype-anti-idiotype dimers in pooled human IgG. J Immunol 1990; 144:1387-95.
59. Kazatchkine MD, Dietrich G, Hurez V et al. V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (IVIg). Immunol Rev 1994; 139:79-107.
60. Dietrich G, Varela F, Hurez V et al. Selection of the expressed B cell repertoire by infusion of normal immunoglobulin G in a patient with autoimmune thyroiditis. Eur J Immunol 1993; 23:2945-50.
61. Ochs HD, Morell A, Skvaril F et al. Survival of IgG subclasses following administration of intravenous gammaglobulin in patients with primary immunodeficiency diseases. In: Morell A and Nydegger UE, eds. Clinical Use of Intravenous Immunoglobulins. London: Academic Press, 1986:77-86.
62. Piechaczyk M, Bouanani M, Salhi SL et al. Antigenic domains on the human thyroglobulin molecule recognized by autoantibodies in patients' sera and by natural autoantibodies isolated from sera of healthy subjects. Clin Immunol Immunopathol 1987; 45:114-21.
63. Dietrich G, Piechaczyk M, Pau B, Kazatchkine MD. Evidence for a restricted idiotypic and epitopic specificity of anti-thyroglobulin autoantibodies in patients with autoimmune thyroiditis. Eur J Immunol 1991; 21:811-4.